Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine total assets
Total assets on the balance sheet at the end of each period.
Editas Medicine's total assets was $219.41M at Sep 30, 2026. For fiscal 2025 it was $186.53M, down 45.4% from the year before. Over ten years it grew 2.2% a year on average. The highest annual figure on record is $677.48M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.53M | -45.4% |
| FY2024 | Dec 31, 2024 | $341.59M | -31.6% |
| FY2023 | Dec 31, 2023 | $499.15M | -2.9% |
| FY2022 | Dec 31, 2022 | $514.32M | -24.1% |
| FY2021 | Dec 31, 2021 | $677.48M | +18.3% |
| FY2020 | Dec 31, 2020 | $572.60M | +12.5% |
| FY2019 | Dec 31, 2019 | $508.89M | +21.1% |
| FY2018 | Dec 31, 2018 | $420.39M | +12.6% |
| FY2017 | Dec 31, 2017 | $373.26M | +62.9% |
| FY2016 | Dec 31, 2016 | $229.18M | +53.4% |
| FY2015 | Dec 31, 2015 | $149.36M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $219.41M | +8.8% |
| Q2 FY2026 | Jun 30, 2026 | $237.36M | +12.7% |
| Q1 FY2026 | Mar 31, 2026 | $149.34M | -43.4% |
| Q4 FY2025 | Dec 31, 2025 | $186.53M | -45.4% |
| Q3 FY2025 | Sep 30, 2025 | $201.75M | -38.4% |
| Q2 FY2025 | Jun 30, 2025 | $210.58M | -45.3% |
| Q1 FY2025 | Mar 31, 2025 | $263.65M | -40.1% |
| Q4 FY2024 | Dec 31, 2024 | $341.59M | -31.6% |
| Q3 FY2024 | Sep 30, 2024 | $327.57M | -35.1% |
| Q2 FY2024 | Jun 30, 2024 | $384.80M | -29.0% |
| Q1 FY2024 | Mar 31, 2024 | $440.35M | -5.1% |
| Q4 FY2023 | Dec 31, 2023 | $499.15M | -2.9% |
| Q3 FY2023 | Sep 30, 2023 | $504.65M | -5.0% |
| Q2 FY2023 | Jun 30, 2023 | $541.95M | -6.7% |
| Q1 FY2023 | Mar 31, 2023 | $464.11M | -25.5% |
| Q4 FY2022 | Dec 31, 2022 | $514.32M | -24.1% |
| Q3 FY2022 | Sep 30, 2022 | $531.03M | -25.9% |
| Q2 FY2022 | Jun 30, 2022 | $580.83M | -23.2% |
| Q1 FY2022 | Mar 31, 2022 | $623.11M | -20.1% |
| Q4 FY2021 | Dec 31, 2021 | $677.48M | +18.3% |
| Q3 FY2021 | Sep 30, 2021 | $717.02M | +20.1% |
| Q2 FY2021 | Jun 30, 2021 | $755.88M | +15.3% |
| Q1 FY2021 | Mar 31, 2021 | $780.29M | +67.2% |
| Q4 FY2020 | Dec 31, 2020 | $572.60M | +12.5% |
| Q3 FY2020 | Sep 30, 2020 | $597.16M | +60.4% |
| Q2 FY2020 | Jun 30, 2020 | $655.48M | +84.3% |
| Q1 FY2020 | Mar 31, 2020 | $466.74M | +23.2% |
| Q4 FY2019 | Dec 31, 2019 | $508.89M | +21.1% |
| Q3 FY2019 | Sep 30, 2019 | $372.36M | -3.9% |
| Q2 FY2019 | Jun 30, 2019 | $355.63M | -9.6% |
| Q1 FY2019 | Mar 31, 2019 | $378.92M | -6.2% |
| Q4 FY2018 | Dec 31, 2018 | $420.39M | +12.6% |
| Q3 FY2018 | Sep 30, 2018 | $387.63M | +14.3% |
| Q2 FY2018 | Jun 30, 2018 | $393.53M | +6.7% |
| Q1 FY2018 | Mar 31, 2018 | $403.98M | +2.3% |
| Q4 FY2017 | Dec 31, 2017 | $373.26M | +62.9% |
| Q3 FY2017 | Sep 30, 2017 | $339.13M | – |
| Q2 FY2017 | Jun 30, 2017 | $368.85M | – |
| Q1 FY2017 | Mar 31, 2017 | $395.04M | – |
| Q4 FY2016 | Dec 31, 2016 | $229.18M | – |
See a number that looks wrong?